• News
  • SAN DIEGO
  • BioTech

Merck to pay $3.85B for hepatitis C drug developer

Merck & Co. will spend about $3.85 billion for Idenix Pharmaceuticals Inc., a small company developing hepatitis C medicines that, together with Merck's experimental drugs, could produce lucrative combo therapies that quickly cure most patients with the blood-borne virus afflicting tens of millions.

To continue reading, subscribe now
or
log in to your account
User Response
0 UserComments
Subscribe Today!